Lv5
1170 积分 2024-08-15 加入
Rechallenge and Extended [ 177 Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer
1个月前
已关闭
Rational Design and Development of an Acyclic Chelator H4pyox for Theranostic Radiometal Labeling under Mild Conditions
1个月前
已完结
Preclinical Investigations to Explore the Difference between the Diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward Prostate Cancer Therapy
1个月前
已完结
Preclinical and First-in-Human Study of Carbonic Anhydrase IX–Targeting Theranostic Pair, [ 68 Ga]Ga/[ 177 Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma
1个月前
已完结
Preclinical Evaluation of68Ga/177Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy
2个月前
已完结
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
3个月前
已关闭
Clinical Implementation of Total-Body PET in China
3个月前
已完结
Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer
3个月前
已完结
Novel [68Ga/177Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy
7个月前
已完结
Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging
9个月前
已完结
皖公网安备34019202002308
